SCHEMBL2159268

SCHEMBL2159268

Cc1cn([C@H]2CC(=NO)[C@@H](CO)O2)c(=O)[nH]c1=O

nearest known ligand 0.56

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TK1 P04183 5/20 0.52
LMNA P02545 3/20 0.52
TSHR P16473 2/20 0.52
ALB P02768 2/20 0.52
BLM P54132 2/20 0.52
PKM P14618 1/20 0.52
PMP22 Q01453 1/20 0.52
CYP2D6 P10635 1/20 0.52
ALDH1A1 P00352 1/20 0.51
POLB P06746 1/20 0.51
ADRA1A P35348 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14232397 0.85 LMNA (0.55) TK1LMNATSHRALBBLM
SCHEMBL2158702 0.85 LMNA (0.55) TK1LMNATSHRALBBLM
SCHEMBL933552 0.84 LMNA (0.54) TK1LMNATSHRALBBLM
SCHEMBL12595723 0.83 TK1 (0.56) TK1LMNATSHRALBBLM
SCHEMBL25966490 0.81 TK1 (0.49) TK1LMNATSHRALBBLM
SCHEMBL18837842 0.77 TK1 (0.66) TK1LMNATSHRALBBLM
SCHEMBL25966495 0.76 TK1 (0.52) TK1LMNAALBBLMPKM
SCHEMBL925743 0.75 LMNA (0.58) TK1LMNATSHRALBBLM
SCHEMBL13286394 0.75 LMNA (0.58) TK1LMNATSHRALBBLM
SCHEMBL762579 0.75 LMNA (0.58) TK1LMNATSHRALBBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110182973-A1 POLYMERASE INHIBITORS AND THE USE THEREOF FOR THE TREATMENT OF TUMORS FREIE UNIVERSITAET BERLIN (DE) 2011-07-28 US claimed
WO-2008138327-A9 POLYMERASE INHIBITORS AND THE USE THEREOF FOR THE TREATMENT OF TUMORS FREIE UNIVERSITÄT BERLIN (DE) 2009-12-30 WO claimed
WO-2008138327-A2 POLYMERASE INHIBITORS AND THE USE THEREOF FOR THE TREATMENT OF TUMORS FREIE UNIVERSITÄT BERLIN (DE) 2008-11-20 WO claimed
EP-1990054-A1 Polymerase inhibitors and their use in treating tumours Freie Universität Berlin (DE) 2008-11-12 EP claimed
US-20110182973-A1 POLYMERASE INHIBITORS AND THE USE THEREOF FOR THE TREATMENT OF TUMORS FREIE UNIVERSITAET BERLIN (DE) 2011-07-28 US disclosed
WO-2008138327-A9 POLYMERASE INHIBITORS AND THE USE THEREOF FOR THE TREATMENT OF TUMORS FREIE UNIVERSITÄT BERLIN (DE) 2009-12-30 WO disclosed
WO-2008138327-A2 POLYMERASE INHIBITORS AND THE USE THEREOF FOR THE TREATMENT OF TUMORS FREIE UNIVERSITÄT BERLIN (DE) 2008-11-20 WO disclosed
EP-1990054-A1 Polymerase inhibitors and their use in treating tumours Freie Universität Berlin (DE) 2008-11-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110182973-A1 POLYMERASE INHIBITORS AND THE USE THEREOF FOR THE TREATMENT OF TUMORS POLH, POLI, POLK TK1 32/4885LMNA 634/4885TSHR 3867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.